Skip to main content
Erschienen in: Familial Cancer 1/2011

01.03.2011 | Early Detection and Diagnosis

An analysis of the efficacy of serial screening for familial nasopharyngeal carcinoma based on Markov chain models

verfasst von: Cheuk Wai Choi, Michael C. H. Lee, Wai Tong Ng, Lai Yau Law, Tsz Kok Yau, Anne W. M. Lee

Erschienen in: Familial Cancer | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Treatment of nasopharyngeal carcinoma (NPC) can be improved by early detection of the disease as treatment outcome worsens with disease’s progression. This can be achieved with a mass screening program using Epstein Barr virus (EBV) serology and nasopharyngoscopy. The efficacy of any screening strategy should be evaluated before putting it into practice. Such evaluation is ideally performed with simulation as time and cost often preclude the evaluation by randomized trial. This study simulated and compared the outcomes of 4 screening strategies over a period of 12 years: (A) Annual screening, (B) biennial screening, (C) triennial screening, and (D) triennial screening for participants tested EBV negative and annual screening once the participants are tested EBV positive. Progression of the disease was divided into 4 phases and calculated by applying Markov chain model. Parameters of the transition matrix and probabilities were estimated using data from previous screening results of 1,072 family members of NPC patients. The early detection rates with strategies A, B, C and D are 88, 79, 71 and 87% respectively. The 5-year overall survival with screening is 10–12% higher than that without and is the highest with strategies A and D. Strategy D, however, requires only 64% screening tests compared with strategy A and has almost identical resultant disease stage distribution to strategy A. We concluded that strategy D offered the highest efficacy for NPC screening of family members of NPC patients among the four strategies studied.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Zeng Y, Zhang LG, Li HY et al (1982) Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer 29(2):139–141CrossRefPubMed Zeng Y, Zhang LG, Li HY et al (1982) Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer 29(2):139–141CrossRefPubMed
2.
Zurück zum Zitat Zeng Y, Zhang LG, Wu YC et al (1985) Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer 36(5):545–547CrossRefPubMed Zeng Y, Zhang LG, Wu YC et al (1985) Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer 36(5):545–547CrossRefPubMed
3.
Zurück zum Zitat Zeng Y, Zhong JM, Li LY et al (1983) Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County, China. Intervirology 20(4):190–194CrossRefPubMed Zeng Y, Zhong JM, Li LY et al (1983) Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County, China. Intervirology 20(4):190–194CrossRefPubMed
4.
Zurück zum Zitat Zong YS, Sham JS, Ng MH et al (1992) Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 69(1):3–7CrossRefPubMed Zong YS, Sham JS, Ng MH et al (1992) Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 69(1):3–7CrossRefPubMed
5.
Zurück zum Zitat Chen JY, Chen CJ, Liu MY et al (1989) Antibody to Epstein-Barr virus-specific DNase as a marker for field survey of patients with nasopharyngeal carcinoma in Taiwan. J Med Virol 27(4):269–273CrossRefPubMed Chen JY, Chen CJ, Liu MY et al (1989) Antibody to Epstein-Barr virus-specific DNase as a marker for field survey of patients with nasopharyngeal carcinoma in Taiwan. J Med Virol 27(4):269–273CrossRefPubMed
6.
Zurück zum Zitat Ng WT, Yau TK, Yung RW et al (2005) Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer 113(6):998–1001CrossRefPubMed Ng WT, Yau TK, Yung RW et al (2005) Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer 113(6):998–1001CrossRefPubMed
7.
Zurück zum Zitat Chen HH, Prevost TC, Duffy SW (1999) Evaluation of screening for nasopharyngeal carcinoma: trial design using Markov chain models. Br J Cancer 79(11–12):1894–1900CrossRefPubMed Chen HH, Prevost TC, Duffy SW (1999) Evaluation of screening for nasopharyngeal carcinoma: trial design using Markov chain models. Br J Cancer 79(11–12):1894–1900CrossRefPubMed
8.
Zurück zum Zitat van Oortmarssen GJ, Boer R, Habbema JD (1995) Modelling issues in cancer screening. Stat Methods Med Res 4(1):33–54CrossRefPubMed van Oortmarssen GJ, Boer R, Habbema JD (1995) Modelling issues in cancer screening. Stat Methods Med Res 4(1):33–54CrossRefPubMed
9.
Zurück zum Zitat van Oortmarssen GJ, Habbema JD, Lubbe JT, van der Maas PJ (1990) A model-based analysis of the HIP project for breast cancer screening. Int J Cancer 46(2):207–213CrossRefPubMed van Oortmarssen GJ, Habbema JD, Lubbe JT, van der Maas PJ (1990) A model-based analysis of the HIP project for breast cancer screening. Int J Cancer 46(2):207–213CrossRefPubMed
10.
Zurück zum Zitat Ng WT, Choi CW, Lee MC, Law LY, Yau TK, Lee AW (2010) Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. Fam Cancer 9(2):221–228CrossRefPubMed Ng WT, Choi CW, Lee MC, Law LY, Yau TK, Lee AW (2010) Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. Fam Cancer 9(2):221–228CrossRefPubMed
11.
Zurück zum Zitat Duffy SW, Chen HH, Tabar L, Day NE (1995) Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Stat Med 14(14):1531–1543CrossRefPubMed Duffy SW, Chen HH, Tabar L, Day NE (1995) Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Stat Med 14(14):1531–1543CrossRefPubMed
12.
Zurück zum Zitat Lee AW, Sze WM, Au JS et al (2005) Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61(4):1107–1116CrossRefPubMed Lee AW, Sze WM, Au JS et al (2005) Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61(4):1107–1116CrossRefPubMed
13.
Zurück zum Zitat Huang DP, Ho JH, Henle W, Henle G (1974) Demonstration of Epstein-Barr virus-associated nuclear antigen in nasopharyngeal carcinoma cells from fresh biopsies. Int J Cancer 14(5):580–588CrossRefPubMed Huang DP, Ho JH, Henle W, Henle G (1974) Demonstration of Epstein-Barr virus-associated nuclear antigen in nasopharyngeal carcinoma cells from fresh biopsies. Int J Cancer 14(5):580–588CrossRefPubMed
14.
Zurück zum Zitat Henle W, Henle G (1977) Evidence for an etiologic relation of the Epstein-Barr virus to human malignancies. Laryngoscope 87(4 Pt 1):467–473PubMed Henle W, Henle G (1977) Evidence for an etiologic relation of the Epstein-Barr virus to human malignancies. Laryngoscope 87(4 Pt 1):467–473PubMed
15.
Zurück zum Zitat Ji MF, Wang DK, Yu YL et al (2007) Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer 96(4):623–630CrossRefPubMed Ji MF, Wang DK, Yu YL et al (2007) Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer 96(4):623–630CrossRefPubMed
16.
Zurück zum Zitat Ung A, Chen CJ, Levine PH et al (1999) Familial and sporadic cases of nasopharyngeal carcinoma in Taiwan. Anticancer Res 19(1B):661–665PubMed Ung A, Chen CJ, Levine PH et al (1999) Familial and sporadic cases of nasopharyngeal carcinoma in Taiwan. Anticancer Res 19(1B):661–665PubMed
17.
Zurück zum Zitat Loh KS, Goh BC, Lu J, Hsieh WS, Tan L (2006) Familial nasopharyngeal carcinoma in a cohort of 200 patients. Arch Otolaryngol Head Neck Surg 132(1):82–85CrossRefPubMed Loh KS, Goh BC, Lu J, Hsieh WS, Tan L (2006) Familial nasopharyngeal carcinoma in a cohort of 200 patients. Arch Otolaryngol Head Neck Surg 132(1):82–85CrossRefPubMed
Metadaten
Titel
An analysis of the efficacy of serial screening for familial nasopharyngeal carcinoma based on Markov chain models
verfasst von
Cheuk Wai Choi
Michael C. H. Lee
Wai Tong Ng
Lai Yau Law
Tsz Kok Yau
Anne W. M. Lee
Publikationsdatum
01.03.2011
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 1/2011
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-010-9397-7

Weitere Artikel der Ausgabe 1/2011

Familial Cancer 1/2011 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.